Aptamer-labeled PLGA nanoparticles for targeting cancer cells

被引：39

作者：

Aravind A. ^{[1
]}

Varghese S.H. ^{[1
]}

Veeranarayanan S. ^{[1
]}

Mathew A. ^{[1
]}

Nagaoka Y. ^{[1
]}

Iwai S. ^{[1
]}

Fukuda T. ^{[1
]}

Hasumura T. ^{[1
]}

Yoshida Y. ^{[1
]}

Maekawa T. ^{[1
]}

Kumar D.S. ^{[1
]}

机构：

[1] Bio-Nano Electronics Research Center, Graduate School of Interdisciplinary New Science, Toyo University, Kawagoe, Saitama

来源：

Cancer Nanotechnology | 2012年 / 3卷 / 1-6期

关键词：

Aptamers; Cancer therapy; Drug delivery; Paclitaxel; PLGA nanoparticles;

D O I：

10.1007/s12645-011-0024-6

中图分类号：

学科分类号：

摘要：

Cancer is one of the leading causes of death in most parts of the world and is a very serious cause of concern particularly in developing countries. In this work, we prepared and evaluated the aptamer-labeled paclitaxel-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Apt-PTX-PLGA NPs) which can ameliorate drug bioavailability and enable accurate drug targeting to cancer cells with controlled drug release for cancer therapy. Paclitaxel-loaded PLGA nanoparticles (PTX-PLGA NPs) were formulated by a single-emulsion/solvent evaporation method and were further surface-functionalized with a chemical cross-linker bis(sulfosuccinimidyl) suberate (BS3) to enable binding of aptamer on to the surface of the nanoparticles. The prepared nanoparticles were characterized by atomic force microscopy, scanning electron microscopy, and X-ray photoelectron spectroscopy. Cytotoxicity studies were carried out using normal human mammary epithelial cells (HMEC cells) and human glial cancer cells (GI-1 cells) by methylthiazolyldiphenyl-tetrazolium bromide assay and Alamar blue assay, which confirmed that PTX-PLGA NPs with aptamer conjugation (Apt-PTX-PLGA NPs) were comparatively non-toxic to HMEC cells while toxic to GI-1 cancer cells. Cellular uptake of PTX-PLGA NPs with and without aptamer conjugation was studied using GI-1 cells and monitored by confocal microscopy and phase contrast microscopy. Our studies demonstrated significant internalization and retention of nanoparticles inside the cells, inducing apoptosis. The preferential accumulation of PTX-PLGA NPs within the cancer cells were also confirmed by flow cytometry-based uptake studies. The results indicated that Apt-PTX-PLGA NPs could be a promising targeted therapeutic delivery vehicle for cancer treatment. © 2012 Springer-Verlag.

引用

页码：1 / 12

页数：11

共 50 条

[1]

Alexandre J., Hu Y., Lu W., Pelicano H., Huang P., Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species, Cancer Res, 67, 8, pp. 3512-3517, (2007)

[2]

Arruebo M., Antibody-conjugated nanoparticles for biomedical applications, J Nanomater 2009, (2009)

[3]

Balamurugan S., Obubuafo A., Soper S.A., Spivak D.A., Surface immobilization methods for aptamer diagnostic applications, Anal Bioanal Chem, pp. 1009-1021, (2008)

[4]

Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O., Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer, Exp Mol Pathol, 86, 3, pp. 151-164, (2009)

[5]

Bob B., Nanoparticle drug delivery systems, Innov Pharm tech, pp. 58-61, (2004)

[6]

Brannon-Peppas L., Blanchette J.O., Nanoparticle and targeted systems for cancer therapy, Advanced Drug Deliv Rev, 56, 11, pp. 1649-1659, (2004)

[7]

Cartiera M.S., Ferreira E.C., Caputo C., Egan M.E., Caplan M.J., Saltzman W.M., Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin, Mol Pharm, 276, 2, (2010)

[8]

Cerchia L., de Franciscis V., Targeting cancer cells with nucleic acid aptamers, Trends Biotechnol, 28, 10, pp. 517-525, (2010)

[9]

Davies C.D.L., Hak S., Hianik T., Aptamer properties, Nucl Phys, 7491, pp. 1-20, (2010)

[10]

Davis S.S., Biomedical applications of nanotechnology-implications for drug targeting and gene therapy, Trends Biotechnol, 15, 6, pp. 217-224, (1997)

← 1 2 3 4 5 →